- Home
- AKRO vs ADNT Comparison
AKRO vs ADNT Comparison
Compare AKRO & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- ADNT
- Stock Information
- Founded
- AKRO 2017
- ADNT 2016
- Country
- AKRO United States
- ADNT Ireland
- Employees
- AKRO N/A
- ADNT N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- ADNT Auto Parts:O.E.M.
- Sector
- AKRO Health Care
- ADNT Consumer Discretionary
- Exchange
- AKRO Nasdaq
- ADNT Nasdaq
- Market Cap
- AKRO 3.9B
- ADNT 1.6B
- IPO Year
- AKRO 2019
- ADNT N/A
- Fundamental
- Price
- AKRO $52.40
- ADNT $22.28
- Analyst Decision
- AKRO Strong Buy
- ADNT Hold
- Analyst Count
- AKRO 6
- ADNT 9
- Target Price
- AKRO $82.50
- ADNT $17.31
- AVG Volume (30 Days)
- AKRO 1.7M
- ADNT 1.5M
- Earning Date
- AKRO 08-08-2025
- ADNT 08-05-2025
- Dividend Yield
- AKRO N/A
- ADNT N/A
- EPS Growth
- AKRO N/A
- ADNT N/A
- EPS
- AKRO N/A
- ADNT N/A
- Revenue
- AKRO N/A
- ADNT $14,384,000,000.00
- Revenue This Year
- AKRO N/A
- ADNT N/A
- Revenue Next Year
- AKRO N/A
- ADNT N/A
- P/E Ratio
- AKRO N/A
- ADNT N/A
- Revenue Growth
- AKRO N/A
- ADNT N/A
- 52 Week Low
- AKRO $21.34
- ADNT $10.04
- 52 Week High
- AKRO $58.40
- ADNT $26.59
- Technical
- Relative Strength Index (RSI)
- AKRO 52.50
- ADNT 79.36
- Support Level
- AKRO $50.13
- ADNT $21.87
- Resistance Level
- AKRO $52.73
- ADNT $22.70
- Average True Range (ATR)
- AKRO 2.09
- ADNT 0.68
- MACD
- AKRO -0.76
- ADNT 0.16
- Stochastic Oscillator
- AKRO 34.00
- ADNT 91.69
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.